COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Long-term Effects of Interventional Strategies to Prevent Cognitive Decline in Elderly. (MAPT-PLUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01513252
Recruitment Status : Unknown
Verified May 2018 by University Hospital, Toulouse.
Recruitment status was:  Recruiting
First Posted : January 20, 2012
Last Update Posted : May 31, 2018
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:
The MAPT PLUS study is a two-year extension of follow-up of the patients included in the MAPT preventive study, after completion of the interventions. Subjects in the four groups of the MAPT study will be prospectively followed. MAPT is a multicentre, randomised, placebo-controlled study, using a 4-group design with 3 treatment groups (omega 3 alone, multi-domain intervention alone, omega 3 plus multi-domain intervention, n=420 each) and a placebo group (n=420). The MAPT PLUS study will be an extension of the MAPT study and includes an annual follow-up for two years.

Condition or disease Intervention/treatment Phase
Frail Elderly Behavioral: Gröber and Buschke test Not Applicable

Detailed Description:

The MAPT PLUS study is a follow-up of subjects initially included in an interventional study. The follow-up that we propose in this request for funding does not involve any intervention, but aims to assess the long-term effect of the interventions previously carried out during the three years of the MAPT study.

* Description of the interventions to which subjects are exposed during the first 3 years of follow-up (MAPT study) :

In the MAPT study, subjects are randomized into 4 groups:

  • V0137 CA group: 2 soft capsules of V0137 CA once a day (2 x 400 mg/day);
  • Multi-domain intervention group (nutrition, physical activity, cognitive stimulation, social activities) + placebo, 2 soft capsules once a day ;
  • Multi-domain intervention group (nutrition, physical activity, cognitive stimulation, social activities) + V0137 CA, 2 soft capsules once a day ;
  • Placebo group: 2 soft capsules of placebo once a day. * Description of the multidomain intervention : The multi-domain intervention consists of collective training sessions and a yearly personalized preventive consultation which aims to detect risk factors (sensory disturbances, difficulty in walking, nutritional disturbances, vascular risk factors) and to set up management in collaboration with the general practitioner.

The collective sessions take place in groups of 6 to 8 subjects. In the first month, two sessions a week are scheduled, and in the second month, one session a week. The first two months correspond to the intensive programme. Each session comprises 1 hour of cognitive training, 45 minutes of information on physical activity and 15 minutes of dietary advice. From the third month, sessions are held monthly and aim to consolidate the key messages and to stimulate adherence to the programme. The sessions are shorter (1 hour review of one of the domains of the intensive programme). " Booster " sessions (2 hours) are delivered at 12 and 24 months after the first sessions of the intensive programme. Twenty-minute individual interviews also take place every 6 months with the leader of the training sessions (6 interviews in the course of 3 years).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1150 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A 2-years Extension Study of MAPT Trial : Evaluation of the Long Term Effects of Interventional Strategies to Prevent the Decline in Cognitive Functioning in Frail Older Adults
Study Start Date : December 2011
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: 1
Gröber and Buschke test
Behavioral: Gröber and Buschke test
spontaneous delayed recall score after a 5 years follow-up

Primary Outcome Measures :
  1. Gröber and Buschke test (spontaneous delayed recall score) [ Time Frame: 2 years ]
    Assessment of cognitive and functional performances according to the spontaneous delayed recall score(Gröber and Buschke test)

  2. Cognitive and functional performance (Gröber and Buschke test-spontaneous delayed recall score) [ Time Frame: 2 years ]
    Assessment of cognitive and functional performances by using the Gröber and Buschke test (spontaneous delayed recall score)at 5 years after the participation to the MAPT study.

Secondary Outcome Measures :
  1. MRI test [ Time Frame: 2 years ]
    Evaluation of the long-term impact of MAPT study interventions on changes in markers of cerebral atrophy (overall brain volume of specific brain structures such as the hippocampus)

  2. Cost-effectiveness Evaluation [ Time Frame: 2 years ]
    Evaluation of the long-term impact of the MAPT interventions in terms of cost-effectiveness ratio by using a medico-economic data collection

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Subjects who meet the following criteria will be included in the MAPT PLUS study :

  • frail elderly subjects participating in the MAPT study and still followed at 3 years,
  • subjects capable of understanding the protocol, complying with its requirements and attending the follow-up visits proposed as part of the extended phase of the MAPT study,
  • subjects capable of giving their written informed consent and complying with the requirements of the study,
  • subjects covered by a health insurance system.

Exclusion Criteria:

Subjects who fulfill at least one of the following criteria will not be included in the MAPT PLUS study :

  • known presence of dementia or Alzheimer's disease (DSM IV criteria) diagnosed during the MAPT follow-up,
  • known presence of severe diseases that are life-threatening in the short term,
  • visual or hearing impairments that are incompatible with performance and/or interpretation of the neuropsychological tests,
  • history and/or presence of any disorder (severe depression or generalized anxiety) which, according to the investigator, is likely to interfere with the results of the study or to expose the subject to a supplementary risk,
  • participation in another clinical study during the period of the present study,
  • subjects who have refused cognitive evaluation during the MAPT follow-up,
  • subjects deprived of their freedom by administrative or judicial decision, or under guardianship,
  • with regard to performance of MRI: presence of a pacemaker or metallic materials, claustrophobia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01513252

Layout table for location information
UH Toulouse - La Grave Recruiting
Toulouse, France, 31059
Contact: Bruno VELLAS, PR    33 5 61 77 64 25   
Contact: Sophie GILLETTE, PHD    33 5 61 77 64 05   
Sponsors and Collaborators
University Hospital, Toulouse
Layout table for investigator information
Principal Investigator: Bruno Vellas, MD University Hospital, Toulouse
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital, Toulouse Identifier: NCT01513252    
Other Study ID Numbers: RC31/11/231
2011-A00764-37 ( Other Identifier: ID-RCB )
First Posted: January 20, 2012    Key Record Dates
Last Update Posted: May 31, 2018
Last Verified: May 2018
Keywords provided by University Hospital, Toulouse:
Cognitive decline
omega-3 fatty acids
nutrition exercise
cognitive training
social activities
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders